This alters the tumour microenvironment and provides in vitro evidence of the interaction between high-dose radiation and the PD-L1/PD1 axis, establishing the basis for the investigation of combination therapy, such as the PD-1 antibody pembrolizumab and radiotherapy [83]. This evidence concerns the gene CD274 and neoplasm.